TUSSIONEX PENNKINETIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TUSSIONEX PENNKINETIC (TUSSIONEX PENNKINETIC).
Tussionex Pennkinetic is a combination of hydrocodone, a mu-opioid receptor agonist, and chlorpheniramine, a histamine H1 receptor antagonist. Hydrocodone binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; it also suppresses cough reflex by direct action on the cough center in the medulla. Chlorpheniramine competitively blocks H1 receptors, reducing symptoms of allergic rhinitis such as sneezing, rhinorrhea, and pruritus.
| Metabolism | Hydrocodone is metabolized primarily by CYP2D6 and CYP3A4 to hydromorphone (active) and other metabolites. Chlorpheniramine is metabolized by CYP2D6 and other pathways. |
| Excretion | Tussionex Pennkinetic (hydrocodone/chlorpheniramine) is primarily excreted renally. Hydrocodone and its metabolites (e.g., hydromorphone, norhydrocodone) are eliminated mainly in urine as conjugates, with approximately 60-70% of the dose recovered in urine over 72 hours, predominantly as glucuronide and sulfate conjugates. Biliary/fecal excretion accounts for about 10-20%, with the remainder via other routes. Chlorpheniramine is extensively metabolized in the liver and excreted renally as metabolites and unchanged drug (less than 1% unchanged). |
| Half-life | Hydrocodone: Terminal elimination half-life is approximately 3.8-4.5 hours in adults. With extended-release formulation (Pennkinetic), the half-life may be prolonged due to slow absorption, but the elimination half-life itself is not significantly altered. Chlorpheniramine: Terminal half-life is approximately 21-27 hours. Clinically, the prolonged half-life of chlorpheniramine contributes to sustained antihistamine effects. |
| Protein binding | Hydrocodone: approximately 30-40% bound to plasma proteins. Chlorpheniramine: approximately 70% bound to plasma proteins, mainly albumin and possibly other proteins. |
| Volume of Distribution | Hydrocodone: Vd is approximately 3-4 L/kg (range 3.0-4.7 L/kg), indicating extensive tissue distribution. Chlorpheniramine: Vd is approximately 3-5 L/kg, also indicating wide distribution. Large Vd suggests high tissue penetration. |
| Bioavailability | Oral bioavailability of hydrocodone is approximately 70-80% (first-pass metabolism). Chlorpheniramine is well absorbed orally with bioavailability of about 25-50% due to extensive first-pass metabolism. For Tussionex Pennkinetic, the extended-release formulation provides sustained absorption. |
| Onset of Action | Oral (extended-release suspension): Peak plasma concentrations are achieved in approximately 1-2 hours for hydrocodone and 3-5 hours for chlorpheniramine. The onset of antitussive effect is typically within 30-60 minutes. |
| Duration of Action | Extended-release formulation provides cough suppression for up to 12 hours per dose. The antihistamine effect of chlorpheniramine lasts longer, typically 12-24 hours. Clinical duration may vary with dosing interval (every 12 hours recommended). |
Oral: 10 mL (equivalent to 10 mg hydrocodone and 10 mg chlorpheniramine) every 12 hours; maximum 20 mL per day.
| Dosage form | SUSPENSION, EXTENDED RELEASE |
| Renal impairment | GFR <30 mL/min: Not recommended due to accumulation of hydrocodone metabolites. |
| Liver impairment | Child-Pugh Class C: contraindicated; Class A or B: reduce dose by 50% or extend interval, monitor closely. |
| Pediatric use | Children ≥6 years: 2.5 mL every 12 hours; maximum 5 mL per day. Children <6 years: contraindicated. |
| Geriatric use | Initiate at lower dose (e.g., 2.5 mL every 12 hours) due to increased sensitivity and renal impairment risk; maximum 5 mL per day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TUSSIONEX PENNKINETIC (TUSSIONEX PENNKINETIC).
| Breastfeeding | Hydrocodone is excreted into breast milk; relative infant dose estimated 2-4% of weight-adjusted maternal dose. M/P ratio not established. Use with caution; monitor infant for sedation and respiratory depression. Chlorpheniramine is excreted in small amounts; generally considered compatible. |
| Teratogenic Risk | First trimester: Data insufficient in humans; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Hydrocodone may cause neonatal opioid withdrawal syndrome (NOWS) with prolonged use. Chlorpheniramine is generally considered low risk; no major malformations reported. |
■ FDA Black Box Warning
WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SEROTONIN SYNDROME. Tussionex Pennkinetic exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Serious, life-threatening, or fatal respiratory depression may occur. Accidental ingestion of even one dose, especially by children, can result in fatal overdose. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome. Concomitant use with CYP3A4 inhibitors or discontinuation of CYP3A4 inducers may increase hydrocodone concentrations. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death. Concomitant use with serotonergic drugs may cause serotonin syndrome.
| Serious Effects |
["Hypersensitivity to hydrocodone, chlorpheniramine, or any component","Significant respiratory depression","Acute or severe bronchial asthma","Known or suspected gastrointestinal obstruction (including paralytic ileus)","Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy"]
| Precautions | ["Addiction, abuse, and misuse","Life-threatening respiratory depression","Accidental ingestion (especially in children)","Neonatal opioid withdrawal syndrome","CYP3A4 and CYP2D6 interactions","Risks from concomitant use with benzodiazepines or other CNS depressants","Serotonin syndrome","Severe hypotension","Gastrointestinal adverse effects (e.g., constipation)","Seizures in patients with seizure disorders","Avoid use in patients with impaired consciousness or coma","Avoid use in patients with known or suspected gastrointestinal obstruction","Use caution in patients with head injury, increased intracranial pressure, or impaired renal/hepatic function"] |
Loading safety data…
| Fetal Monitoring | Assess fetal growth and amniotic fluid index with prolonged use due to potential opioid effects. Monitor for signs of neonatal opioid withdrawal if used near term. Assess maternal respiratory status and sedation level. Urine drug screening recommended if abuse suspected. |
| Fertility Effects | No known direct effects on fertility. Opioid use may disrupt menstrual cycle and reduce libido; chlorpheniramine has no known adverse fertility effects. |